This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter A. Selwyn, MD, MPH; Blanca M. Sckell, MD, MPH; Philip Alcabes, MPH; Gerald H. Friedland, MD; Robert S. Klein, MD; Ellie E. Schoenbaum, MD

JAMA. 1992;268(4):504-509.

Abstract
Objectives.
—To determine the incidence of active tuberculosis in human immunodeficiency virus (HIV)—seropositive and HIV-seronegative drug injectors with cutaneous anergy and to examine the effectiveness of isoniazid chemoprophylaxis in preventing tuberculosis among drug injectors with positive tuberculin test results.

Design and Setting.
—Prospective observational study linked to an ongoing study of HIV infection within a New York City (NY) methadone program; subjects also underwent routine intradermal tuberculin testing and multiple-antigen delayed-type hypersensitivity skin testing. The 31-month study period ended December 31, 1990.

Methods.
—Anergic subjects and tuberculin reactors who were HIV seropositive were compared by HIV disease status and CD4⁺ T-lymphocyte levels. Tuberculosis incidence was calculated for anergics (none treated with isoniazid) and for treated and untreated tuberculin reactors, by HIV serological status.

Results.
—Among those seropositive for HIV, anergic subjects had more advanced HIV disease and fewer CD4⁺ cells (median 0.33 vs 0.56 x10⁹/L, P<.01) compared with tuberculin reactors, although neither clinical status nor CD4⁺ cell counts consistently predicted anergy. Five (7.6%) of 68 anergic subjects who were HIV seropositive and none of 52 anergic subjects who were HIV seronegative (n=18) or of unknown (n=34) HIV serological status developed active tuberculosis during the study period (P<.05). The tuberculosis incidence rate among anergic subjects who were HIV seropositive was 6.6 cases per 100 person-years (95% confidence interval [CI], 2.1 to 15.3). Of 25 HIV-seropositive tuberculin reactors who did not receive or complete 12 months of isoniazid prophylaxis, tuberculosis incidence was 9.7 cases per 100 person-years (95% CI, 2.6 to 24.7; P=0.56, compared with the rate among anergic HIV seropositives); there were no cases of tuberculosis in 53.4 person-years of follow-up for 27 HIV-seropositive tuberculin reactors who received 12 months of prophylaxis (rate difference between treated and untreated groups, 9.7 cases per 100 person-years, 95% CI, 1.3 to 18.0).

Conclusion.
—Drug injectors with cutaneous anergy who are seropositive for HIV are at high risk of active tuberculosis, similar to that among untreated HIV-seropositive tuberculin reactors. A decreased incidence of active tuberculosis was seen in HIV-seropositive tuberculin reactors receiving 12 months of isoniazid chemoprophylaxis, compared with untreated or partially treated subjects. These results support the routine use of delayed-type hypersensitivity testing to accompany tuberculin testing for drug injectors with known or suspected HIV infection, and consideration of isoniazid prophylaxis for anergic as well as tuberculin-reactive subjects who are HIV seropositive, in populations with a high prevalence of coexisting HIV and Mycobacterium tuberculosis infection.

(JAMA. 1992;268:504-509)

Author Affiliations
From the Department of Epidemiology and Social Medicine (Drs Selwyn, Sckell, Friedland, Klein, and Schoenbaum and Mr Alcabes) and Department of Medicine, Division of Infectious Disease (Drs Friedland, Klein, and Schoenbaum), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. Drs Selwyn and Friedland are currently with the AIDS Program, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Conn.

Footnotes
Reprint requests to AIDS Program, Yale-New Haven Hospital, Yale University School of Medicine, Welch Building, 20 York St, New Haven, CT 06504 (Dr Selwyn).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molecular Epidemiology of Tuberculosis: Current Insights
Mathema et al.
Clin. Microbiol. Rev. 2006;19:658-685.
ABSTRACT | FULL TEXT  

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States
Am. J. Respir. Crit. Care Med. 2005;172:1169-1227.
FULL TEXT  

To control and beyond: moving towards eliminating the global tuberculosis threat
Brewer and Heymann
J. Epidemiol. Community Health 2004;58:822-825.
ABSTRACT | FULL TEXT  

Tuberculosis presenting as pancoast tumor
Beshay et al.
Ann. Thorac. Surg. 2003;76:1733-1735.
ABSTRACT | FULL TEXT  

Tuberculosis and HIV: A Partnership Against the Most Vulnerable
Cahn et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:106-123.
ABSTRACT  

The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett et al.
Arch Intern Med 2003;163:1009-1021.
ABSTRACT | FULL TEXT  

Comparison of a Whole-Blood Interferon {gamma} Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium tuberculosis Infection
Mazurek et al.
JAMA 2001;286:1740-1747.
ABSTRACT | FULL TEXT  

Strategies to Decrease Tuberculosis in US Homeless Populations: A Computer Simulation Model
Brewer et al.
JAMA 2001;286:834-842.
ABSTRACT | FULL TEXT  

Benefits of Screening for Latent Mycobacterium tuberculosis Infection
Rose
Arch Intern Med 2000;160:1513-1521.
ABSTRACT | FULL TEXT  

The Case Against Anergy Testing as a Routine Adjunct to Tuberculin Skin Testing
Slovis et al.
JAMA 2000;283:2003-2007.
ABSTRACT | FULL TEXT  

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999.
Am. J. Respir. Crit. Care Med. 2000;161:S221-247.
FULL TEXT  

Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial
Gordin et al.
JAMA 2000;283:1445-1450.
ABSTRACT | FULL TEXT  

How does tuberculosis relate to HIV positive and HIV negative drug users?
Keizer et al.
J. Epidemiol. Community Health 2000;54:64-68.
ABSTRACT | FULL TEXT  

Admission Trends in a Rural South African Hospital During the Early Years of the HIV Epidemic
Floyd et al.
JAMA 1999;282:1087-1091.
ABSTRACT | FULL TEXT  

Tuberculosis Prevention in Methadone Maintenance Clinics . Effectiveness and Cost-Effectiveness
SNYDER et al.
Am. J. Respir. Crit. Care Med. 1999;160:178-185.
ABSTRACT | FULL TEXT  

Tuberculosis in AIDS: past or new problems?
MAYAUD and CADRANEL
Thorax 1999;54:567-571.
FULL TEXT  

Preventive Therapy for Tuberculosis in HIV Infection
Brewer
JAMA 1999;281:881-882.
FULL TEXT  

Instability of Tuberculin and Candida Skin Test Reactivity in HIV-infected Ugandans
JOHNSON et al.
Am. J. Respir. Crit. Care Med. 1998;158:1790-1796.
ABSTRACT | FULL TEXT  

Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count
Sawert et al.
Arch Intern Med 1998;158:2112-2121.
ABSTRACT | FULL TEXT  

Use of Health Care Services in a Sample of Drug-Involved Offenders: A Comparison With National Norms
McCORKEL et al.
American Behavioral Scientist 1998;41:1079-1089.
ABSTRACT  

Processing of Mycobacterium tuberculosis Bacilli by Human Monocytes for CD4+ alpha beta and gamma delta T Cells: Role of Particulate Antigen
Balaji and Boom
Infect. Immun. 1998;66:98-106.
ABSTRACT | FULL TEXT  

Skin Anergy Testing and Tuberculosis Surveillance
Lincoln et al.
J Correct Health Care 1997;4:139-153.
ABSTRACT  

A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus
Whalen et al.
NEJM 1997;337:801-808.
ABSTRACT | FULL TEXT  

Isoniazid Preventive Therapy in Human Immunodeficiency Virus-Infected Persons: Long-term Effect on Development of Tuberculosis and Survival
Moreno et al.
Arch Intern Med 1997;157:1729-1734.
ABSTRACT  

A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for Tuberculosis
Gordin et al.
NEJM 1997;337:315-320.
ABSTRACT | FULL TEXT  

Incidence of Tuberculosis in Injection Drug Users in San Francisco . Impact of Anergy
DALEY et al.
Am. J. Respir. Crit. Care Med. 1997;157:19-22.
ABSTRACT | FULL TEXT  

Evaluation of Tuberculosis Control Policies Using Computer Simulation
Brewer et al.
JAMA 1996;276:1898-1903.
ABSTRACT  

Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease
Graham et al.
Arch Intern Med 1996;156:889-894.
ABSTRACT  

Tuberculosis, AIDS, and Death among Substance Abusers on Welfare in New York City
Friedman et al.
NEJM 1996;334:828-833.
ABSTRACT | FULL TEXT  

Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection
Caiaffa et al.
Arch Intern Med 1995;155:2111-2117.
ABSTRACT  

Isoniazid Preventive Therapy in Areas of High Isoniazid Resistance
Sterling et al.
Arch Intern Med 1995;155:1622-1628.
ABSTRACT  

Risk Factors for Tuberculosis in HIV-lnfected Persons: A Prospective Cohort Study
Antonucci et al.
JAMA 1995;274:143-148.
ABSTRACT  

National Trends in the Concurrence of Tuberculosis and Acquired Immunodeficiency Syndrome
Burwen et al.
Arch Intern Med 1995;155:1281-1286.
ABSTRACT  

Mycobacterium tuberculosis Infection in Pregnant and Nonpregnant Women Infected With HIV in the Women and Infants Transmission Study
Mofenson et al.
Arch Intern Med 1995;155:1066-1072.
ABSTRACT  

Global Epidemiology of Tuberculosis: Morbidity and Mortality of a Worldwide Epidemic
Raviglione et al.
JAMA 1995;273:220-226.
ABSTRACT  

Medical Care for Injection-Drug Users with Human Immunodeficiency Virus Infection
O'Connor et al.
NEJM 1994;331:450-459.
FULL TEXT  

Failure of Tuberculosis Control: A Prescription for Change
Bellin
JAMA 1994;271:708-709.
ABSTRACT  

Tuberculosis and AIDS: Epidemiologic, Clinical, and Social Dimensions
Selwyn
J Law Med Ethics 1993;21:279-288.
 

Tuberculosis in Prison: Balancing Justice and Public Health
Greifinger et al.
J Law Med Ethics 1993;21:332-341.
 

Preventive Services Guidelines for Primary Care Clinicians Caring for Adults and Adolescents Infected With the Human Immunodeficiency Virus
Gerber et al.
Arch Fam Med 1993;2:969-979.
ABSTRACT  

Addiction Medicine
Franklin
JAMA 1993;270:184-185.
ABSTRACT  

Drug-Resistant Tuberculosis in New York City
Gensheimer et al.
NEJM 1993;329:134-135.
FULL TEXT  

Recent Advances in Pulmonary Medicine- Second of Two Parts
Weinberger
NEJM 1993;328:1462-1470.
FULL TEXT  

Association of Tuberculosis Infection With Increased Time in or Admission to the New York City Jail System
Bellin et al.
JAMA 1993;269:2228-2231.
ABSTRACT  

Preventive Health Care for Adults With HIV Infection
Jewett and Hecht
JAMA 1993;269:1144-1153.
ABSTRACT  

Tuberculosis in Anergic HIV-Infected Drug Users
Abeles et al.
JAMA 1993;269:473-474.
ABSTRACT